Innovate UK’s Post

Yet again, the data speaks for itself...there is clear confidence in the UK's ATMP manufacturing capability and infrastructure as it continues to grow year-on-year. With the skilled workforce growing by 7%, the cleanroom footprint growing by 12% and in-house QC increasing by 15% And this growth is an outcome of some great UK manufacturing successes this year: - RoslinCT manufacturing the world's first CRISPR-edited therapy for Vertex Pharmaceuticals (with the Medicines and Healthcare products Regulatory Agency giving the world's first approval) - Autolus Therapeutics having their BLA accepted and achieving licensure of their own commercial manufacturing facility - Adaptimmune having their BLA accepted - Quell Therapeutics expanding their manufacturing in the newly licensed eXmoor Pharma facility And various other successes which I've inevitably missed (sorry to anyone I've missed out!) Innovate UK Department for Science, Innovation and Technology Department for Business and Trade

"The overall picture of dedicated GMP cell therapy manufacturing over the past year is positive, notably with a 100% increase in the median number of cleanrooms per facility and a 42% increase in in-house QC laboratory footprint. The number of full-time employees and the overall cleanroom footprint have also both increased by 23%" It's an exciting time for QC in pharma. Moreover, With Cell and Gene Therapy treatments becoming increasingly available since 2020, we are beginning to the real impact of bringing cures to patients.

The UK is quickly becoming a pioneer in producing cell and gene therapies, a therapeutic area with the potential to treat many currently incurable diseases 🧬 Our client, The Cell and Gene Therapy Catapult, has released their annual report on the UK's GMP manufacturing capability regarding #AdvancedTherapies. Finding; 🔬The UK now produces 199 pre-clinical, clinical, and commercial therapies. 📈The number of commercially licensed products has increased from 2 to 6, showing significant progress. 🏭There are now 32 MHRA-licensed GMP facilities, with new sites increasing capacity in workforce and cleanroom footprint. The key next steps for this exciting area are to ensure the UK has the operating environment and a skilled workforce to develop these crucial therapies and realise their impact! Find out more below! ⬇️

🚀 Exciting news from the Cell and Gene Therapy Catapult! The release of the 2024 Good Manufacturing Practice (GMP) Report showcases the continued growth of the UK’s manufacturing infrastructure for #AdvancedTherapies #ATMPs #CellandGeneTherapy #UK

The Cell and Gene Therapy Catapult has released its Good Manufacturing Practice (GMP) Report 2024 which highlights continued growth in the UK's manufacturing infrastructure for #AdvancedTherapies. Key findings from the report, which is based on a survey of organisations in the UK, include: - Six commercially licensed products now produced in the UK ✔️ - An increase in licensed facilities 🏭 - An increase in full-time employees 🥼 Read the report: https://lnkd.in/eeTz7_kP #CellTherapy #GeneTherapy #ATMPs

Exciting news! 🔊 Cell and Gene Therapy Catapult has released its 2024 GMP Report yesterday! 🧬   This report highlights exciting progress in the industry, showcasing growth in licensed products, expanded facilities, and specialist employees! 🏭🥼 These advancements are essential as we move towards the wider adoption of cell and gene therapies, ensuring the UK remains a leader in global manufacturing.   Read the full report below ⬇️⬇️⬇️   #CellTherapy #GeneTherapy #Innovation

Cell and Gene Therapy Catapult has once again published its GMP Report and we are delighted to be included for the first year as an MHRA (IMP) licensed facility for multifunctional cell and gene therapy manufacturing! It's clear the UK manufacturing landscape is strong with 6 commercially licensed products now being produced in the UK and significant growth in the CGT workforce. Today we celebrate the successes of the entire UK Advanced Therapy community 👏

The number of global gene therapies in clinical trials has seen a veritable explosion in recent years. In the U.S., the largest pools of drug discovery and pre-clinical research talent are concentrated on or near the east and west coasts, accounting for some 90% of investigators. Nevertheless, there are pockets of this talent in the Midwest and South Central regions that are not only less saturated but also more cost-attractive than most coastal and near coastal metros. #GeneTherapy #DrugDiscovery #PreClinicalResearch #LocationStrategy

NEWS ALERT: The first patient has been dosed in our TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial, marking a significant step forward in our journey to transform care for individuals living with PKP2-associated #ARVC. This milestone reflects our unwavering commitment to discover, develop and deliver potentially curative therapies that address the underlying drivers of #heartdisease. Read more: https://lnkd.in/eqfwvcQU #HCM #GeneTherapy #Biotech

How is investment in the cell and gene therapy sector shaping up this year? Our data shows that through the first half of 2024, there have been over $11 billion in deals, approaching the annual total for 2023. Dive into ARM's full quarterly data on investments, clinical trials, and total developers on our website. 📊 https://lnkd.in/ebVuvmKK #cellandgenetherapy #data